Advertisement

Critical Care

, 23:354 | Cite as

Attainment of therapeutic vancomycin level within the first 24 h: Authors' response

  • João Pedro BaptistaEmail author
  • Jason A. Roberts
  • Eduardo Sousa
  • Ricardo Freitas
  • Nuno Devesa
  • Jorge Pimentel
Open Access
Letter

In sepsis, time is life. However, time is not the only variable of the complex equation of antibiotic therapy; the dose of antibiotic administered needs to be adequate. Subtherapeutic antibiotic concentrations potentially lead to decreased microbial killing, treatment failure, and emergence of resistance and/or increased mortality. Early therapeutic drug monitoring and timely dose optimization, ideally during the first 24 h, minimize the likelihood of subtherapeutic antibiotic concentrations and ineffective antibiotic therapy. Vancomycin remains a first-line option for the treatment of methicillin-resistant Staphylococcus aureus and other resistant Gram-positive bacteria. Of note, vancomycin is one of the antibiotics with the highest likelihood of under dosing [1]. Continuous infusion (CI), after adequate loading dose (LD), seems to have pharmacological advantages in the critically ill and enables more consistent achievement of therapeutic exposures.

A nomogram for dosing vancomycin can be easily used at the bedside of the patient, providing rapidly personalized dosing. One of the key factors facilitating the nomogram is the fact that renal clearance of vancomycin is strongly correlated with the measured urinary creatinine clearance (CLCR). Unfortunately, it is more common in clinical practice to use the less accurate mathematical estimates of renal function in unstable patients, instead of measured CLCR [2]. Such an approach serves to compromise the reliability of the nomogram in the critical care setting.

We appreciate and read with interest the comments of Honoré et al., regarding our study in 2014, where we developed and validated a dosing nomogram for vancomycin in CI in a population of critically ill patients [3, 4]. Some clarifications, however, are needed. First, we never intended to compare CI with a LD of vancomycin; instead, we used, sequentially, LD (between 1 and 1.5 g) followed by CI (30 mg/kg/day). Later, with nomogram-guided dosing using an 8 h-CLCR, we achieved target vancomycin exposures in 84% of patients in the validation group in the first 24 h. Of these, 40% had demonstrated augmented renal clearance (8 h-CLCR > 130 mL/min/1.73m2). Secondly, patients with compromised renal function or needing of renal replacement therapy were excluded in our study, meaning that our nomogram should not be considered applicable to this group of patients. Third, the volume of distribution and the half-life of vancomycin increases significantly in critically ill patients with renal insufficiency. On the other hand, vancomycin (medium molecular size molecule) is effectively cleared by continuous renal replacement therapies (CRRT). Considering the large inter-study variability, there is no clear recommendation about the optimal vancomycin regimen during CRRT [5]. A vancomycin loading dose of 15–20 mg/kg actual body weight would likely be more appropriate in CRRT patients. Finally, future studies confirming our dosing protocol are welcome; however, the chosen target population should be similar (with exclusion of patients under CRRT) so that the obtained results can be extrapolated to different contexts.

Notes

Acknowledgements

None

Authors’ contributions

JPB conceived the study and wrote the initial draft, with all of the remaining authors contributing to subsequent revisions. All of the authors have read and approved the final article for publication.

Funding

None

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

JAR: Consultancies/Advisory Boards – MSD (2019); QPEX (2019); Discuva Ltd. (2019); Accelerate Diagnostics (2017); Bayer (2017); Biomerieux (2016). Speaking Fees – MSD (2018); Biomerieux (2018). Industry Grants – MSD (2017); The Medicines Company (2017); Cardeas Pharma (2016); Biomerieux (2019).

All the other authors declare that they have no competing interests.

References

  1. 1.
    Al-Dorzi HM, Eissa AT, Khan RM, Harbi SAA, Aldabbagh T, Arabi YM. Dosing errors of empirical antibiotics in critically ill patients with severe sepsis or septic shock: a prospective observational study. Int J Health Sci (Qassim). 2019;13(4):48–55.Google Scholar
  2. 2.
    Baptista JP, Neves M, Rodrigues L, Teixeira L, Pinho J, Pimentel J. Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients. J Nephrol. 2014;27(4):403–10.CrossRefGoogle Scholar
  3. 3.
    Honore PM, De Bels D, Attou R, Redant S, Gallerani A, Kashani K. Attainment of therapeutic vancomycin level within the first 24 h. Crit Care. 2019;23:228.CrossRefGoogle Scholar
  4. 4.
    Baptista JP, Roberts JA, Sousa E, Freitas R, Deveza N, Pimentel J. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. Crit Care. 2014;18(6):654.CrossRefGoogle Scholar
  5. 5.
    Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med. 2014;42(7):1640–50.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of Intensive Care MedicineCentro Hospitalar e Universitário de CoimbraCoimbraPortugal
  2. 2.University of Queensland Centre for Clinical Research, Faculty of Medicine & Centre for Translational Anti-infective Pharmacodynamics, School of PharmacyThe University of QueenslandBrisbaneAustralia
  3. 3.Departments of Pharmacy and Intensive Care MedicineRoyal Brisbane and Women’s HospitalBrisbaneAustralia
  4. 4.Division of Anaesthesiology Critical Care Emergency and Pain MedicineNîmes University Hospital, University of MontpellierNîmesFrance
  5. 5.Emeritus Associated Professor on Intensive Care MedicineCoimbraPortugal

Personalised recommendations